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Introduction {#sec004}
============

Atrial fibrillation (AF) is the most common cardiac arrhythmia found in clinical practice and is associated with an increased risk of morbidity \[[@pone.0227262.ref001]\]. As we known, there is strong independent association between diabetes and AF. Moreover, studies also showed fasting glucose levels were positively and independently correlated with incident AF in patients with diabetes, which suggested the important role of glycemic control on preventing the AF. However, results from Action to Control Cardiovascular Risk in Diabetes trial showed that intensive glycaemic control in people with diabetes have no significant effect on the rate of new-onset atrial fibrillation and cardiovascular outcomes.

Hemoglobin A1c (HbA1c), a major component of hemoglobin-glucose adducts, reflects the average blood glucose level within the prior 2 to 3 months and has been a well-accepted biomarker for glycemic management in diabetes patients over the past several decades\[[@pone.0227262.ref002]\]. In recent years, an elevated level of HbA1c has been shown to be linked to an increased risk of cardiovascular diseases (e.g., myocardial infarction and AF)) in patients with and without diabetes \[[@pone.0227262.ref003]\]. The association between HbA1c and AF has been investigated in previous studies. However, the evidence is inconsistent \[[@pone.0227262.ref004]--[@pone.0227262.ref009]\]. In the Atherosclerosis Risk in Communities cohort, Huxley et al\[[@pone.0227262.ref005]\] found that high HbA1c was an independent risk factor for incident AF in patients with and without diabetes. A meta-analysis also found that serum levels of HbA1c in diabetes patients with AF were higher than those in diabetes patients without AF (standardized mean difference = 0.67)\[[@pone.0227262.ref010]\]. Conversely, the results of the Women\'s Health Study showed that there was no association between any category of HbA1c level (4.84%-5.0%, 5.0%-5.19%, \>5.19%) and risk of AF after adjusting for potential covariates\[[@pone.0227262.ref011]\]. Recent, several new studies with large population were published, still with inconsistent results\[[@pone.0227262.ref012], [@pone.0227262.ref013]\]. Moreover, several new research articles have reported that a higher serum HbA1c could reduce new-onset AF after coronary artery bypass grafting (CABG) surgery \[[@pone.0227262.ref014], [@pone.0227262.ref015]\]. Given this background, we conducted a dose-response meta-analysis to i) quantitatively investigate the dose-specific relationship between HbA1c and AF. ii) estimate whether serum HbA1c could reduce post-operation AF (POAF) after CABG.

Methods {#sec005}
=======

Literature search {#sec006}
-----------------

This work has been performed according to PRISMA guidelines ([http://www.prisma-statement.org](http://www.prisma-statement.org/); **[S1 Table](#pone.0227262.s003){ref-type="supplementary-material"}**). We systematically searched the Cochrane Library, PubMed, and Embase databases for eligible studies before March 10, 2019.Two groups of keywords (linked to hemoglobin A1c, and AF, respectively) were combined using the Boolean operator \"and\". **[S2 Table](#pone.0227262.s004){ref-type="supplementary-material"}** provides a detailed description of the search strategy in the aforementioned electronic databases. In addition, we searched the reference lists of two review or other relevant publications to identify further studies. No language restrictions were applied in the whole literature search.

Study selection {#sec007}
---------------

Studies were considered eligible if they: (1) designed as randomized controlled trials (RCTs) or observational cohorts; (2) reported the impact of hemoglobin A1c and AF; (3) made available a quantitative measure of hemoglobin A1c and the number of AF cases in each hemoglobin A1c category for the dose-response analysis. For multiple publications/reports created from the same data, the studies with the longest follow-up period or the largest number of AF cases were included. In addition, certain publication types (e.g., reviews, editorials, letters, conference abstracts, and animal studies), or studies with insufficient data were excluded from this analysis. Post-hoc analyses of RCTs can be equivalent to observational studies.

Data extraction and quality assessment {#sec008}
--------------------------------------

For each study, the basic characteristics were extracted, mainly including the first author, publication year, geographical location, study type, participants (sex, age, and sample size), duration of follow-up, adjustments for confounders, AF type (on-set or recurrence) methods of measuring hemoglobin A1c levels, categories of hemoglobin A1c and adjusted risk ratios (RRs) (categorical or continuous) with its 95% confidence intervals (CIs). If both unadjusted and adjusted RRs existed in one study, we extracted the most completely adjusted one. For multiple publications/reports with the same data, we included the article with the most recent or the largest number of participants.

We used the Newcastle-Ottawa quality assessment scale (NOS) to evaluate the quality for all included studies\[[@pone.0227262.ref004]\]. Post hoc analysis of RCTs was treated as cohort studies to achieve quality assessment\[[@pone.0227262.ref016]\]. The validated NOS items with a total of 9 stars involved three aspects including the selection of population, the comparability of study, and the assessment of the outcome. In this meta-analysis, a NOS score of ≥6 stars was regarded as high-quality, otherwise, as low-quality studies\[[@pone.0227262.ref005]\].

Statistical analyses {#sec009}
--------------------

Both linear and nonlinear models were performed. We calculated study-specific RR (hemoglobin A1c per 1% increase) and 95% CIs from the natural logs of the reported RRs and CIs across categories of hemoglobin A1c by using the method of Greenland and Longnecker\[[@pone.0227262.ref006]\]. Summary RRs and 95% CIs for a 1% increment in hemoglobin A1c were pooled using a random effects model. RRs and 95%CI were calculated from the number of AF and cases in different HbA1c levels when them were not directly provided. All data were analyzed by Review Manager version 5.30 software (the Nordic Cochrane Center, Rigshospitalet, Denmark) and Stata software (Version 14.0, Stata Corp LP, College Station, Texas, USA). We performed the non-linear dose-response analysis by using the robust error meta-regression method (REMR) described by Xu et al.\[[@pone.0227262.ref007]\] This method is based on a "one-stage approach" which treating each study as a cluster of the whole sample and considering the within study correlations by clustered robust error. It requires known levels of hemoglobin A1c and RRs with variance estimates for at least two quantitative exposure categories. For studies that did not set the highest hemoglobin A1c group as a reference, data were transformed using a method described by Hamling et al.\[[@pone.0227262.ref008]\] which requires the number of cases and participants in each category. If these data could not be obtained from an article, the evidence was not pooled. The category hemoglobin A1c concentration within each study for dose-response meta-analysis was calculated according to the methods of previous study. To assess the heterogeneity of RRs across studies, the I2 (95% CI) statistic was calculated with the following interpretation: low heterogeneity, defined as I2 \< 50%; moderate heterogeneity, defined as I2 50% to 75%; and high heterogeneity, defined as I2 \>75%\[[@pone.0227262.ref009]\]. If there was evidence of publication bias, we additionally applied trim and fill methods to adjust for publication bias. Sensitivity analyses excluding one study at a time were conducted to clarify whether the results were simply due to one large study or a study with an extreme result. A P value \< 0.05 was considered statistically significant.

Results {#sec010}
=======

Study selection {#sec011}
---------------

Our comprehensive retrieval identified 1,836 studies in our initial database search. After removing duplicates and studies with inadequate information on HbA1c and AF, 22 studies were reviewed in more detail. After checking the full text, 8 were excluded for the following reasons: a) they were focused on recurrent AF (n = 1); b) they were reviews or case reports (n = 2); or c) they were investigating the association between glucose tolerance and AF (n = 4); d) they were using data from another study that was retrieved (n = 1). Finally, 14 studies were included in this meta-analysis \[[@pone.0227262.ref004]--[@pone.0227262.ref009], [@pone.0227262.ref013]--[@pone.0227262.ref015], [@pone.0227262.ref017]--[@pone.0227262.ref021]\] (**[S1 Fig](#pone.0227262.s001){ref-type="supplementary-material"}**).

Study characteristics and quality {#sec012}
---------------------------------

Detailed characteristics of the included studies are presented in **[Table 1](#pone.0227262.t001){ref-type="table"}**. Fourteen studies \[[@pone.0227262.ref004]--[@pone.0227262.ref009], [@pone.0227262.ref014], [@pone.0227262.ref015], [@pone.0227262.ref017]--[@pone.0227262.ref021]\] with 17,914 AF cases among 352,325 participants were included in this meta-analysis. These studies were published between 2008 and 2017. The sample sizes of the included studies varied from 82 to 52,448. The mean age ranged from 53 to 72 years. Among the fourteen articles, six \[[@pone.0227262.ref004], [@pone.0227262.ref009], [@pone.0227262.ref013], [@pone.0227262.ref017], [@pone.0227262.ref019], [@pone.0227262.ref021]\] included diabetes or prediabetes patients, four \[[@pone.0227262.ref006]--[@pone.0227262.ref008], [@pone.0227262.ref018]\] included subjects without known diabetes and four \[[@pone.0227262.ref005], [@pone.0227262.ref014], [@pone.0227262.ref015], [@pone.0227262.ref020]\] studies reported both population with or without diabetes. Eight \[[@pone.0227262.ref004]--[@pone.0227262.ref009], [@pone.0227262.ref013], [@pone.0227262.ref018]\] studies examined the serum HbA1c status and AF, and 6\[[@pone.0227262.ref014], [@pone.0227262.ref015], [@pone.0227262.ref017], [@pone.0227262.ref019]--[@pone.0227262.ref021]\] focused on POAF in patients undergoing CABG.

10.1371/journal.pone.0227262.t001

###### Basic characteristics of the 14 articles included in the meta-analysis.

![](pone.0227262.t001){#pone.0227262.t001g}

  Author, publication year, country                    Population, Study design, follow-up duration                                      Source of participant, Cases/N                                 Definition of AF, Measurement H1Ac1, Mean age (years), male (%)           H1Ac1 expose level                        RR (95%CI)                                                Adjustment for confounders
  ---------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Halkos, 2008, USA \[[@pone.0227262.ref015]\]         CABG, Retrospective cohort, NA                                                    Emory University Hospital, 549/3089                            ECG, NA, 63, 73                                                           Per 1%                                    0.89(0.80--0.98)                                          age, female, caucasian, renal failure, stroke, NYHA class IV,CCS class, main disease, No. diseased vessels, chronic lung disease, arrhythmia, peripheral vascular disease, perioperative factors. intraoperative glucose, postoperative glucose, arterial grafts, vein grafts, total grafts, CPB time, CPB used, LITA or BITA used
  Matsuura, 2009, Japan \[[@pone.0227262.ref019]\]     CABG, Retrospective cohort, 2.1 years                                             Chiba University Hospital, 26/101                              NA, ion capture assay, 65, 79                                             Per 1%                                    0.87(0.64--1.19)[^\#^](#t001fn003){ref-type="table-fn"}   NA
  Tsuruta, 2011, Japan \[[@pone.0227262.ref021]\]      CABG, Prospective cohort, 3.6 years                                               Juntendo University Hospital of Japan, 36/305                  NA, NA, 60, 79                                                            \<6.5%;                                   Ref                                                       NA
  6.5%-7.5%                                            0.89(0.36--2.21)                                                                                                                                                                                                                                                                                                               
  ≥7.5%                                                1.25(0.58--2.71)                                                                                                                                                                                                                                                                                                               
  Per 1%.                                              1.12(0.76--1.65)                                                                                                                                                                                                                                                                                                               
  Kinoshita, 2012, Japan \[[@pone.0227262.ref014]\]    CABG, Case-control, NA                                                            Shiga University of Medical Science, 159/805                   ECG, high-performance liquid chromatography, 68, 80                       3.8--5.6%                                 Ref                                                       age, sex, BMI, chronic kidney disease, chronic pulmonary disease, hypertension, triple vessel disease, ejection fraction of \<40%, left atrial dimension, preoperative beta blockers, preoperative statins, inotropic support for \>24 h, and transfusion
  6.8--11.4%                                           0.55 (0.35--0.88)                                                                                                                                                                                                                                                                                                              
  per 1%                                               0.78(0.63--0.95)                                                                                                                                                                                                                                                                                                               
  Surer, 2016,Turkey \[[@pone.0227262.ref020]\]        CABG, Retrospective cohort, NA                                                    Diskapi Yildirim Beyazit Training & Research Hospital, 12/72   ECG, liquid chromatography, 63, 56                                        Per 1%                                    3.92(1.92--7.99)                                          NA
  Abbaszadeh, 2017, Iran \[[@pone.0227262.ref017]\]    CABG, Prospective cohort, 1 years                                                 Tehran University of Medical Sciences, 109/708                 ECG, immunoturbidimetric, 61, 61                                          Per 1%                                    1.06(0.93--1.2)                                           age, duration of diabetes, COPD, renal failure and hypertension, postoperative use of beta-blockers and calcium channel blockers, left atrial size, cardiopulmonary pump duration, and cross clamp time
  Dublin, 2010, USA \[[@pone.0227262.ref006]\]         Population-based, Prospective case-control, 9.4 years                             Group Health database of Research Institute of US, 1410/3613   GH electronic data, calculated by total glycosylated hemoglobin, 70, 41   5%[\*](#t001fn002){ref-type="table-fn"}   Ref                                                       age, sex, calendar year, treated hypertension, and BMI
  ≤7%                                                  1.06(0.74--1.51)                                                                                                                                                                                                                                                                                                               
  7--8%                                                1.48(1.09--2.01)                                                                                                                                                                                                                                                                                                               
  8--9%                                                1.46(1.02--2.08)                                                                                                                                                                                                                                                                                                               
  \>9%                                                 1.96(1.22--3.14)                                                                                                                                                                                                                                                                                                               
  Per 1%                                               1.14(0.96--1.35)                                                                                                                                                                                                                                                                                                               
  Huxley, 2012, USA \[[@pone.0227262.ref005]\]         DM or non-DM, Prospective cohort study, 14.5 years                                ARIC study, 1311/13025                                         ECG; high-performance liquid chromatography, 57, 44                       Per 1% (non-DM)                           1.05(0.96--1.15)                                          age, study site, education, income, prevalent CHD, BMI, systolic BP, antihypertensive medications, and smoking
  Per 1% (DM)                                          1.13(1.07--1.20)                                                                                                                                                                                                                                                                                                               
  Iguchi, 2012, Japan \[[@pone.0227262.ref018]\]       Population-based, Prospective cohort, NA                                          Kurashiki city Public Health Center, 1161/52448                ECG, NA, 72, 34                                                           Per 1%                                    1.18(1.09--1.28)                                          age, sex, BMI, chronic kidney disease, COPD, hypertension, triple vessel disease, ejection fraction of \<40%, left atrial dimension, preoperative beta blockers, preoperative statins, inotropic support for \>24 h, and transfusion
  Turgut, 2013, Turkey \[[@pone.0227262.ref009]\]      DM, Retrospective Case-control, NA                                                Cumhuriyet University of Turkey, 81/162                        Medical records, turbidimetric immunoinhibition assay, 63, 52             Per 1%                                    1.87(0.747--3.014)                                        age, male gender, HT, smoking, history of CAD, previous CVA, microalbuminuria, retinopathy, duration of diabetes, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, platelet count, and MPV
  Latini,2013, Italy \[[@pone.0227262.ref004]\]        Population with impaired glucose tolerance, Post hoc analysis of RCT, 6.5 years   NAVIGATOR study, 613/8943                                      ECG or investigator-reported event, NA, 63, 49                            Per 1%                                    1.11 (0.91--1.32)                                         age, height, abnormal ECG, heart rate, COPD, BP, weight, hypertension, eGFR, fasting plasma glucose, CHF, race, CHD outcomes, platelet
  Sandhu, 2014, Canada \[[@pone.0227262.ref008]\]      Population-based(women), Prospective cohort, 16.4 years                           Women's Health Study, 1039/34720                               ECG or medical report, NA, 53, 0                                          Paroxysmal AF                                                                                       interim MI, stroke, revascularization, and HF
  Per 1%                                               1.08(0.95--1.22)[^\#^](#t001fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                        
  ≤4.84%                                               Ref                                                                                                                                                                                                                                                                                                                            
  4.84--5.00%                                          0.90(0.69--1.17)                                                                                                                                                                                                                                                                                                               
  5.00--5.19%                                          0.99(0.77--1.27)                                                                                                                                                                                                                                                                                                               
  \>5.19%                                              0.76(0.58--1.00)                                                                                                                                                                                                                                                                                                               
  Nonparoxysmal AF                                                                                                                                                                                                                                                                                                                                                                    
  ≤4.84%                                               Ref                                                                                                                                                                                                                                                                                                                            
  4.84--5.00%                                          1.30(0.85--1.97)                                                                                                                                                                                                                                                                                                               
  5.00--5.19%                                          1.43(0.96--2.15)                                                                                                                                                                                                                                                                                                               
  \>5.19%                                              1.48(0.98--2.22)                                                                                                                                                                                                                                                                                                               
  Blasco, 2014, Spain \[[@pone.0227262.ref007]\]       AMI, Prospective cohort, 8 days                                                   University Clinic Hospital of Valencia, 12/601                 ECG, ion-exchange high-performance liquid chromatography, 62, 78          \<5.5%                                    Ref                                                       age, sex, classical cardiovascular risk factors, Killip class, history of previous MI, serum creatinine, serum glycaemia, systolic, BP and heart rate on admission.
  5.5--6.4%                                            1.68(0.64--4.39)                                                                                                                                                                                                                                                                                                               
  \>6.4%                                               29.74(10.79--81.94)                                                                                                                                                                                                                                                                                                            
  per 1%                                               3.24(2.41--4.35)[^\#^](#t001fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                        
  Dahlqvist, 2017, Sweden \[[@pone.0227262.ref013]\]   type 1 diabetes, prospective case-control study                                   Swedish National Diabetes Registry, 1283/ 216852               ECG, 35.4, 55                                                             Control                                   Ref                                                       age, sex, education level, birthplace, country of birth, diabetes duration, level of education, mean systolic BP, BMI, HDL cholesterol, and LDL cholesterol, and time-updated smoking, use of blood pressure-lowering medication, use of lipid-lowering drugs, and insulin delivery method, CAD, HF, valve disease, stroke, and cancer
  \<6.9                                                1.03(0.84--1.27)                                                                                                                                                                                                                                                                                                               
  7.0--7.8                                             1.11(0.97--1.28)                                                                                                                                                                                                                                                                                                               
  7.8--8.7                                             1.28(1.12--1.47)                                                                                                                                                                                                                                                                                                               
  8.8--9.6                                             1.4(1.15--1.69)                                                                                                                                                                                                                                                                                                                
  \>9.7                                                2.32(1.8--2.99)                                                                                                                                                                                                                                                                                                                
  Per 1%                                               1.14(1.06--1.24)                                                                                                                                                                                                                                                                                                               

Abbreviations: CABG = coronary artery bypass grafting; DM = diabetes mellitus; AMI = acute myocardial infarction; ARIC = The Atherosclerosis Risk in Communities study; H1Ac1 = Hemoglobin A1c; ECG = electrocardiogram; AF = atrial fibrillation; COPD = chronic obstructive pulmonary disease. NYHA = New York Heart Association; BMI = Body Mass Index HDL = high density lipoprotein; CPB = cardiopulmonary bypass; CCS = Canadian Cardiovascular Society; LITA BITA = bilateral internal thoracic artery; eGFR = estimated creatinine clearance; CHD = Coronary heart disease; HF = heart failure; BP = blood pressure; CAD = coronary artery disease; NAVIGATOR = Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research. NA = not available.

\* H1Ac1 level of no history of DM

\#Calculated from the number of AF occurrence in different HbA1c levels

We used the Newcastle-Ottawa Scale score to evaluate the quality of the included articles\[[@pone.0227262.ref022]\]. Only two studies were scored as low quality, with a NOS score of 5. The other twelve were scored as high quality (score ≥6) (**[S3 Table](#pone.0227262.s005){ref-type="supplementary-material"}**).

Dose-response association between circulating HbA1c and incident AF {#sec013}
-------------------------------------------------------------------

Eight studies \[[@pone.0227262.ref004], [@pone.0227262.ref005], [@pone.0227262.ref007]--[@pone.0227262.ref009], [@pone.0227262.ref011], [@pone.0227262.ref013], [@pone.0227262.ref018]\] with 16,516 cases among 344,709 participants were included in the dose-response analysis of HbA1c and AF. The summary RR for a 1% increase in HbA1c was 1.16 (95% CI: 1.07--1.27, I^2^ = 52%, P = 0.0004) **([Fig 1](#pone.0227262.g001){ref-type="fig"})**. Heterogeneity was reduced to 0% when excluding one study with short follow-up (acute myocardial infarction patients)\[[@pone.0227262.ref007]\], and the results were still significant (RR = 1.14, 95% CI: 1.09--1.19). In the sensitivity analysis conducted by omitting one study at a time, the pooled results were not significantly changed.

![Forest plot of the association between HbA1c level and risk of atrial fibrillation, per 1% increase in HbA1c.](pone.0227262.g001){#pone.0227262.g001}

In addition, in the subgroup of patients, the results were still positive in diabetes or impaired glucose tolerance patients (RR = 1.13, 95% CI: 1.08--1.19, I^2^ = 0%, P\<0.0001) **([Fig 2](#pone.0227262.g002){ref-type="fig"})**, with no evidence of heterogeneity. The result was still significant in subjects without known diabetes patients (RR = 1.12, 95% CI: 1.05--1.20, I^2^ = 17%, P = 0.0009), with no evidence of heterogeneity.

![Forest plot of HbA1c and atrial fibrillation incidence among diabetes or unknown diabetes, per 1% increase in HbA1c.](pone.0227262.g002){#pone.0227262.g002}

Moreover, we conducted a nonlinear dose-response analysis to investigate the dose-specific effects between HbA1c and AF. Because of data restriction, the diabetes population was not included in this nonlinear model. We found a nonlinear (P~nonlinear~ = 0.04) relationship between HbA1c and AF **([Fig 3](#pone.0227262.g003){ref-type="fig"})** in subjects without known diabetes. The curves showed that HbA1c over 6.3% significantly increased the risk of AF. The curves did not change significantly when the AMI patients were excluded.

![HbA1c and risk of atrial fibrillation in patients with unknown diabetes, nonlinear dose-response analysis.\
The solid line and the dashed lines represent the estimated relative risk and the 95% confidence interval, respectively.](pone.0227262.g003){#pone.0227262.g003}

Association between HbA1c and POAF in patients undergoing CABG {#sec014}
--------------------------------------------------------------

Six\[[@pone.0227262.ref014], [@pone.0227262.ref015], [@pone.0227262.ref017], [@pone.0227262.ref019]--[@pone.0227262.ref021]\] studies that included 1,335 cases and 7,616 patients were included in this analysis. Serum HbA1c (per 1% increase) was not associated with POAF incidence (RR: 1.00, 95% CI: 0.84--1.20, I^2^ = 79%, P = 0.96) **([Fig 4](#pone.0227262.g004){ref-type="fig"})**. The results did not significantly change when the univariate analysis was excluded (RR: RR: 0.92, 95% CI: 0.80--1.06, I^2^ = 72%, P = 0.27).

![Forest plot of HbA1c and atrial fibrillation incidence in patients undergoing coronary artery bypass, per 1% increase in HbA1c.](pone.0227262.g004){#pone.0227262.g004}

In the subgroup, serum HbA1c (per 1% increase) was not associated with the risk of AF in subjects with diabetes (RR: 1.08, 95% CI: 0.86--1.36, I^2^ = 82%, P = 0.52) or without known diabetes (RR: 0.91, 95% CI: 0.73--1.12, P = 0.37) **([S2 Fig](#pone.0227262.s002){ref-type="supplementary-material"}).** Nonlinear dose-response analysis was not possible because of limited information.

Publication bias {#sec015}
----------------

The funnel plots for AF (N = 8) and POAF (N = 6) were not evaluated due to the limited number of studies (N\<10), according to the guideline \[[@pone.0227262.ref023]\].

Discussion {#sec016}
==========

To the best of our knowledge, this is the first meta-analysis to evaluate the dose-response association between HbA1c and AF. Our results showed evidence of a positive nonlinear dose-response association between HbA1c and AF. For every 1% increase in HbA1c level, the risk of AF increased by 28%. The association was positive in diabetes patients and subjects without diabetes or with unknown diabetes status. Interestingly, unlike in previous reports, elevated serum HbA1c level was not a protective factor for AF in patients after CABG, whether in diabetes or in nondiabetes.

A previous meta-analysis reported a weak association between HbA1c and the risk of AF in prospective studies; however, no positive association was observed in the primary analysis\[[@pone.0227262.ref024]\]. The inconsistent results between the previous study and ours might have several reasons. First, diabetes patients and subjects without known diabetes were combined for analysis. The relationship between HbA1c and AF in diabetes patients and subjects without known diabetes is still unknown. Another problem is that the general population and CABG patients were also combined for analysis in their primary results. This might not be appropriate because patients with CABG have great heterogeneity compared with the general population. Third, not all of the available studies could not be pooled because of the types of methods used in their study (semi-quantitative). More importantly, only pooling category-specific relative risks and their confidence intervals (e.g. highest vs lowest) leading to a bias in statistics. In contrast to the previous meta-analysis, our results suggest that increased serum HbA1c levels were associated with an increased risk of AF in diabetes patients using the dose-response method. In the linear model, the summary RRs for per 1% increase in HAb1Ac were positive, both in patients with or without known diabetes. Moreover, in the non-linear model, we found there is a nonlinear (P~nonlinear~ = 0.04) relationship between HbA1c and AF in patients without known diabetes. The dose-specific curve showed that HbA1c over 6.3% significantly increased the risk of AF, and rose steeply thereafter. These results are consistent with an article that found a significant positive correlation between HbA1c levels and the duration of AF (r = 0.408, p = 0.005) and worse cardiovascular outcomes\[[@pone.0227262.ref025]\], thereby suggesting the important role of abnormal glucose metabolism in increasing AF burden. Several underlying pathophysiological mechanisms might explain this association. First, long-term high levels of HbA1c could induce the production of advanced glycation end products (AGEs) and increase the level of tissue growth factor, causing atrial structural remodeling and atrial enlargement\[[@pone.0227262.ref026]\]. On the other hand, it has been proposed that AGEs, including HbA1c, may play a crucial role in atrial remodeling via the induction of reactive oxygen species and may eventually cause electrolyte imbalance and systemic inflammation\[[@pone.0227262.ref027]\]. All of the above effects may lead to greater AF vulnerability.

Moreover, our study extended the association between HbA1c and AF risk. Our dose-response curves showed that HbA1c\>6.3% significantly increased the risk of AF in subjects without diabetes or with unknown diabetes status. Considering the close association between hyperglycemic state and AF, this result was not surprising. Hyperglycemia not only could prolong the atrial conduction times and P wave dispersion in prediabetic patients but also was an important risk factor for AF even in healthy populations without comorbidities \[[@pone.0227262.ref028], [@pone.0227262.ref029]\]. In fact, several meta-analyses also showed that HbA1c\>6.3% significantly increased the cardiovascular mortality and risk of events in the diabetic population \[[@pone.0227262.ref030]\]. Thus, our findings reinforce the idea that HbA1c is a potential factor in algorithms to calculate cardiovascular risk in clinical settings\[[@pone.0227262.ref031]\]. We also noted that a study based type 1 diabetes population showed that the threshold of HbA1c level increasing the AF risk was 7.8%-8.7%\[[@pone.0227262.ref013]\]. These results suggested that in people with untreated diabetes, the cardiovascular risk (such as AF) may be higher compared with known patients with diabetes, which might emphasize the importance of screening and treatment for diabetes.

We did not find a protective role of HbA1c in POAF, in both individuals with diabetes and without diabetes or with unknown diabetes status. However, we should interpret these results with caution. First, the number of including studies was limited. Only one study examined the association between HbA1c and POAF in nondiabetic patients. Second, there was significant heterogeneity in the results of POAF. Because of a limited number of included studies (N\<10), meta-regression was not performed, according to the guideline \[[@pone.0227262.ref023]\]. Therefore, the source of heterogeneity was not identified, and it may have come from the study design or baseline characteristics of the patients. Furthermore, it is notable that only half (N = 3)\[[@pone.0227262.ref014]\] of the included studies adjusted for potential clinical covariates in their results, and the other studies did not analyze the association between HbA1c and AF in multivariate regression analyses. Many clinical covariates and many important clinical confounding factors (e.g., anti-arrhythmia drugs) were not fully adjusted for, which might have influenced the risk of POAF. In addition, the sample size in the majority of included studies was relatively small. Thus, larger, well-designed studies are needed to explore whether there was a protective effect of preoperative HbA1c on POAF in patients undergoing CABG.

Study limitations {#sec017}
-----------------

The present meta-analysis has several limitations. First, although majority of studies adjusted the potential confounding (e.g. age, sex, BMI), this was a meta-analysis of observational studies, which cannot directly prove causation, and the unmeasured and insufficiently measured variables could have resulted in residual confounding. Second, there was substantial heterogeneity among our primary and subgroup analyses of POAF, which may have come from different study designs and patient baseline values. Third, the HbA1c level was measured only once, at baseline, in all of the included studies. Thus, regression dilution bias may have been induced in our results because of the within-subject variation in HbA1c level and measurement error.

Conclusion {#sec018}
==========

Our dose-response results suggest that serum higher HbA1c was associated with an increased risk of AF, both in diabetes and without diabetes or with unknown diabetes status. However, no association was found between HbA1c and POAF in patients after CABG. Undoubtedly, because of the limited sample size and significant heterogeneity among the included studies, these conclusions should be interpreted with caution, and further well-designed studies with larger sample sizes are needed to explore the association between serum HbA1c level and the risk of POAF.

Supporting information {#sec019}
======================

###### Flowchart of study selection.

(DOCX)

###### 

Click here for additional data file.

###### Forest plot of HbA1c and atrial fibrillation incidence among diabetes and non-diabetes patients undergoing coronary artery bypass, per 1% increase.
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